Credo Diagnostics Biomedical Pte. Ltd

Singapore, April 21, 2023 – Update on Detection of the Influenza A subtypes

Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of Influenza A H3N8 subtype listed in GISAID, NCBI, and BV-BRC.

Our analysis has confirmed that our assays maintain their stated level of performance.

*The Influenza A virus detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ Flu/RSV Assay (PCRAE0106)
． VitaPCR™ Flu A&B Assay (PCRAE0103)

For more information, contact us at service@credodxbiomed.com.

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

Singapore, April 11, 2023 – Update on Detection of the latest SARS-CoV-2 Variant

Credo Diagnostics Biomedical Pte Ltd continues the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using BLASTn analysis comparing primers and probes of the assays involving SARS-CoV-2 virus detection to the sequences listed in GISAID from January 1st, 2023 to March 31st, 2023.

We are pleased to announce that our VitaPCR™ system is capable of detecting the Omicron XBB.1.9.1 and XBB.1.16 subvariants and our analysis has confirmed that the performance of our SARS-CoV-2 RNA detection assays* is not impacted by the Omicron subvariant, XBB.1.9.1 and XBB.1.16.

*The SARS-CoV-2 RNA detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
． VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)

For more information, contact us at service@credodxbiomed.com.

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

Singapore, March 2^nd, 2023 – Update on Detection of the Influenza A subtypes

Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method, comparing primers and probes of the assays involving Influenza A virus detection to the sequences of Influenza A H3N2, H1N1, H5N1, and H7N9 subtypes listed in GISAID, NCBI, and BV-BRC up until 31st January 2023.

Our analysis has confirmed that our assays maintain their stated level of performance.

*The Influenza A virus detection assays include:
． VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
． VitaPCR™ Flu/RSV Assay (PCRAE0106)
． VitaPCR™ Flu A&B Assay (PCRAE0103)

For more information, contact us at service@credodxbiomed.com.

About Credo Diagnostics Biomedical Pte. Ltd.

Credo Diagnostics develops and manufactures innovative, easy-to-use, and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas of Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.